Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAR-T cells in the treatment of relapsed and refractory hematological malignancies

Next Previous
X
Search
Trial Profile

CAR-T cells in the treatment of relapsed and refractory hematological malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inaticabtagene autoleucel (Primary) ; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Gemcitabine; Melphalan; Rituximab; Stem cell therapies
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Dec 2022 Results (n=21; From December 2017 through May 2021) assessing updated enrollment, efficacy, and 2-year follow-up of CNCT19 with HDT/ASCT in refractory large B-cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 09 Jan 2021 New trial record
    • 08 Dec 2020 Preliminary results (n=13) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top